Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Long-Term Investments (2017 - 2025)

Historic Long-Term Investments for Syndax Pharmaceuticals (SNDX) over the last 5 years, with Q3 2025 value amounting to $20.1 million.

  • Syndax Pharmaceuticals' Long-Term Investments rose 10087.75% to $20.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.1 million, marking a year-over-year increase of 10087.75%. This contributed to the annual value of $119.5 million for FY2024, which is 30068.39% up from last year.
  • Syndax Pharmaceuticals' Long-Term Investments amounted to $20.1 million in Q3 2025, which was up 10087.75% from $62.6 million recorded in Q2 2025.
  • Over the past 5 years, Syndax Pharmaceuticals' Long-Term Investments peaked at $119.5 million during Q4 2024, and registered a low of $5.5 million during Q4 2022.
  • Moreover, its 4-year median value for Long-Term Investments was $20.1 million (2025), whereas its average is $39.9 million.
  • In the last 5 years, Syndax Pharmaceuticals' Long-Term Investments skyrocketed by 44541.96% in 2023 and then crashed by 3614.14% in 2024.
  • Quarter analysis of 4 years shows Syndax Pharmaceuticals' Long-Term Investments stood at $5.5 million in 2022, then surged by 445.42% to $29.8 million in 2023, then surged by 300.68% to $119.5 million in 2024, then plummeted by 83.14% to $20.1 million in 2025.
  • Its Long-Term Investments was $20.1 million in Q3 2025, compared to $62.6 million in Q2 2025 and $89.9 million in Q1 2025.